Journal article
Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates
J Li, F Ahmet, LC Sullivan, AG Brooks, SJ Kent, R De Rose, AM Salazar, C Reis e Sousa, K Shortman, MH Lahoud, WR Heath, I Caminschi
European Journal of Immunology | Published : 2015
Abstract
Targeting antigens to dendritic cell (DC) surface receptors using antibodies has been successfully used to generate strong immune responses and is currently in clinical trials for cancer immunotherapy. Whilst cancer immunotherapy focuses on the induction of CD8+ T-cell responses, many successful vaccines to pathogens or their toxins utilize humoral immunity as the primary effector mechanism. Universally, these approaches have used adjuvants or pathogen material that augment humoral responses. However, adjuvants are associated with safety issues. One approach, successfully used in the mouse, to generate strong humoral responses in the absence of adjuvant is to target antigen to Clec9A, also k..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
M.H.L., K.S, W.R.H and I.C. are supported by project grants from the National Health and Medical Research Council of Australia (NHMRC). K.S, S.J.K. and W.R.H. are supported by an NHMRC Program grant. W.R.H. is supported by an NHMRC fellowship. C.R.S. is supported by Cancer Research UK and the European Research Council. L.C.S is supported by an NHMRC career development award. J.L. is the recipient of an Australian Postgraduate Award PhD Scholarship. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Independent Research Institute Infrastructure Support Scheme.